432 related articles for article (PubMed ID: 18824064)
1. Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.
Durkin S; Prendergast A; Harkin A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1894-901. PubMed ID: 18824064
[TBL] [Abstract][Full Text] [Related]
2. Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine.
Callaghan PD; Farrand K; Salem A; Hughes P; Daws LC; Irvine RJ
Eur J Pharmacol; 2006 Sep; 546(1-3):74-81. PubMed ID: 16925993
[TBL] [Abstract][Full Text] [Related]
3. Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine.
Harkin A; Shanahan E; Kelly JP; Connor TJ
Eur J Neurosci; 2003 Aug; 18(4):1021-7. PubMed ID: 12925028
[TBL] [Abstract][Full Text] [Related]
4. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
Sanchez V; Camarero J; Esteban B; Peter MJ; Green AR; Colado MI
Br J Pharmacol; 2001 Sep; 134(1):46-57. PubMed ID: 11522596
[TBL] [Abstract][Full Text] [Related]
5. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.
O'Shea E; Esteban B; Camarero J; Green AR; Colado MI
Neuropharmacology; 2001; 40(1):65-74. PubMed ID: 11077072
[TBL] [Abstract][Full Text] [Related]
6. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
7. Ethanol, 3,4-methylenedioxymethamphetamine (ecstasy) and their combination: long-term behavioral, neurochemical and neuropharmacological effects in the rat.
Cassel JC; Riegert C; Rutz S; Koenig J; Rothmaier K; Cosquer B; Lazarus C; Birthelmer A; Jeltsch H; Jones BC; Jackisch R
Neuropsychopharmacology; 2005 Oct; 30(10):1870-82. PubMed ID: 15785779
[TBL] [Abstract][Full Text] [Related]
8. Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter.
Kramer HK; Poblete JC; Azmitia EC
Neuropsychopharmacology; 1997 Sep; 17(3):117-29. PubMed ID: 9272479
[TBL] [Abstract][Full Text] [Related]
9. A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test.
Gigliucci V; Buckley KN; Nunan J; O'Shea K; Harkin A
Pharmacol Biochem Behav; 2010 Feb; 94(4):524-33. PubMed ID: 19945477
[TBL] [Abstract][Full Text] [Related]
10. Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats.
Thompson MR; Li KM; Clemens KJ; Gurtman CG; Hunt GE; Cornish JL; McGregor IS
Neuropsychopharmacology; 2004 Apr; 29(4):694-704. PubMed ID: 14627999
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 fatty acid deficiency does not alter the effects of chronic fluoxetine treatment on central serotonin turnover or behavior in the forced swim test in female rats.
McNamara RK; Able JA; Liu Y; Jandacek R; Rider T; Tso P; Lipton JW
Pharmacol Biochem Behav; 2013 Dec; 114-115():1-8. PubMed ID: 24090922
[TBL] [Abstract][Full Text] [Related]
12. Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes.
Bianchi M; Moser C; Lazzarini C; Vecchiato E; Crespi F
Exp Brain Res; 2002 Mar; 143(2):191-7. PubMed ID: 11880895
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the discriminative stimulus effects of S(+)-3,4-methylenedioxymethamphetamine (MDMA) by (+/-)-MDMA neurotoxicity: protection by fluoxetine.
Virden TB; Baker LE
Behav Pharmacol; 1999 Mar; 10(2):195-204. PubMed ID: 10780832
[TBL] [Abstract][Full Text] [Related]
14. Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR.
Colado MI; Granados R; O'Shea E; Esteban B; Green AR
Br J Pharmacol; 1998 Jun; 124(3):479-84. PubMed ID: 9647471
[TBL] [Abstract][Full Text] [Related]
15. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats.
Hewitt KE; Green AR
Neuropharmacology; 1994 Dec; 33(12):1589-95. PubMed ID: 7539115
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats.
Walker QD; Williams CN; Jotwani RP; Waller ST; Francis R; Kuhn CM
Psychopharmacology (Berl); 2007 Jan; 189(4):435-45. PubMed ID: 17019566
[TBL] [Abstract][Full Text] [Related]
17. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine.
Colado MI; O'Shea E; Granados R; Murray TK; Green AR
Br J Pharmacol; 1997 Jul; 121(5):889-900. PubMed ID: 9222545
[TBL] [Abstract][Full Text] [Related]
18. Dissociation of the neurochemical and behavioral toxicology of MDMA ('Ecstasy') by citalopram.
Piper BJ; Fraiman JB; Owens CB; Ali SF; Meyer JS
Neuropsychopharmacology; 2008 Apr; 33(5):1192-205. PubMed ID: 17609680
[TBL] [Abstract][Full Text] [Related]
19. Interaction between the forced swimming test and fluoxetine treatment on extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the rat.
Kirby LG; Lucki I
J Pharmacol Exp Ther; 1997 Aug; 282(2):967-76. PubMed ID: 9262365
[TBL] [Abstract][Full Text] [Related]
20. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.
Colado MI; Murray TK; Green AR
Br J Pharmacol; 1993 Mar; 108(3):583-9. PubMed ID: 7682129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
